Knowing what to look for and how to manage the changes can make a difference. Secondary progressive MS (SPMS) can affect both physical health and cognitive abilities. Results from a small 2025 ...

A new study reveals that mitochondrial dysfunction plays a central role in the loss of Purkinje neurons in the cerebellum, ...

"With no treatment options currently available for the broad population of patients with secondary progressive multiple sclerosis, tolebrutinib has demonstrated its ability to delay disability by ...

Multiple sclerosis (MS) affects an estimated 2.3 million people worldwide. Approximately 80% of people with MS have ...

IMUX stock's drop appears to be an overreaction, given positive disability progression data and clean safety profile. Click ...

Shares of Tiziana Life Sciences climbed after the company said it has expanded a Phase 2 clinical trial that is underway of its treatment for multiple sclerosis, an autoimmune condition that affects ...

Tiziana (TLSA) is showing groundbreaking advancements in Alzheimer's & MS treatments with foralumab. Key trials & market ...

Enrollment is now complete in two Phase 3 clinical trials testing vidofludimus calcium in adults with relapsing forms of ...

In this randomized controlled trial of patients with nonrelapsing secondary progressive multiple sclerosis (SPMS), oral ...

Tiziana Life Sciences to Present at the Bio International ConventionNEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology ...

Multiple sclerosis is a long-term autoimmune disorder in which the immune system mistakenly attacks the protective sheath ...